(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.16%) $0.928
(0.33%) $10.88
(0.01%) $0.792
(0.03%) $92.60
Live Chart Being Loaded With Signals
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions...
Stats | |
---|---|
Today's Volume | 21 069.00 |
Average Volume | 14 765.00 |
Market Cap | 13.61M |
EPS | $0 ( 2024-02-12 ) |
Next earnings date | ( $-0.780 ) 2024-05-13 |
Last Dividend | $0.0450 ( 2018-06-01 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0200 |
ATR14 | $0.0650 (1.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Banks Jerel A. | Buy | 466 554 | Options (right to buy) |
2024-03-06 | Boston Megan | Buy | 200 004 | Options (right to buy) |
2023-12-06 | Smith Edward F | Buy | 35 000 | Options (right to buy) |
2023-12-06 | Francis Peter | Buy | 35 000 | Options (right to buy) |
2023-12-06 | Buchi J Kevin | Buy | 35 000 | Options (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 38 transactions |
Buy: 2 361 696 | Sell: 57 465 |
Benitec Biopharma Inc Correlation
10 Most Positive Correlations | |
---|---|
RNLX | 0.862 |
TTSH | 0.842 |
BAFN | 0.831 |
OVLY | 0.829 |
VIOT | 0.826 |
GGAL | 0.826 |
ASLE | 0.824 |
CASH | 0.823 |
BOOM | 0.82 |
TELA | 0.818 |
10 Most Negative Correlations | |
---|---|
MBCN | -0.811 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Benitec Biopharma Inc Financials
Annual | 2023 |
Revenue: | $75 000.00 |
Gross Profit: | $-306 000 (-408.00 %) |
EPS: | $-14.12 |
Q4 | 2023 |
Revenue: | $7 000.00 |
Gross Profit: | $-77 000.00 (-1 100.00 %) |
EPS: | $-2.83 |
Q3 | 2023 |
Revenue: | $54 000.00 |
Gross Profit: | $22 000.00 (40.74 %) |
EPS: | $-2.71 |
Q2 | 2023 |
Revenue: | $14 000.00 |
Gross Profit: | $-27 000.00 (-192.86 %) |
EPS: | $-3.27 |
Financial Reports:
No articles found.
Benitec Biopharma Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0450 | 2018-06-01 |
Last Dividend | $0.0450 | 2018-06-01 |
Next Dividend | $0 | N/A |
Payout Date | 2018-06-08 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.0450 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2018 | $0.0450 | 0.01% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -358.57 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.024 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.05 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.62 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.55 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.55 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0198 | -1.500 | 9.67 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -1 446.13 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -7.01 | 2.00 | -2.34 | -4.67 | [0 - 30] |
freeCashFlowPerShareTTM | -7.01 | 2.00 | -3.51 | -7.01 | [0 - 20] |
debtEquityRatioTTM | 0.0273 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.820 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -355.61 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -42.71 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00286 | 0.800 | -3.31 | -2.65 | [0.5 - 2] |
Total Score | -1.934 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.604 | 1.000 | -0.162 | 0 | [1 - 100] |
returnOnEquityTTM | -2.05 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -7.01 | 2.00 | -2.34 | -7.01 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -7.01 | 2.00 | -2.34 | -4.67 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00176 | 1.500 | -3.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -296.16 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -3.45 |
Benitec Biopharma Inc
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators